FDA to Launch Pilot Program on Model-Informed Drug Development

Drug Industry Daily
A A
The FDA announced a new pilot program in which drug sponsors can meet with agency officials to discuss strategies for model-informed drug development (MIDD) to make their clinical trials more efficient and increase the chances of regulatory approval.

To View This Article:

Login

Subscribe To Drug Industry Daily